additional navigation


You are here:

Current studies

Focus: Myeloproliferative diseases/neoplasms

Essential thrombocythemia indication: Name of Study ARETA

  • Essential thrombocythemia indication: Name of Study ARETA Anagrelide Retard vs. Placebo: Efficacy and safety in “at-risk” patients with essential thrombocythemia (ARETA). The study consists of a multicenter, phase III , randomized, subject and sponsor-blinded, placebo-controlled study to determine the effect of “anagrelide retard” on subjects with essential thrombocythemia (ET) at “defined risk.”

Polycythemia vera indication: Name of study PEGINVERA

  • Safety study of pegylated interferon alpha 2b to treat polycythemia vera (PEGINVERA).
  • The goal of this study is to identify the maximum tolerated dose (MTD) of the medication under investigation. Moreover, the safety and tolerability will be assessed and an exploratory analysis of efficacy and biomaker modulation will be performed.

Indication: polyzythämia vera
Name of study: PROUD-PV

  • Pegylated interferon alpha-2b versus hydroxyurea in polycythemia vera
  • The PROUD-PV study is a phase III study to compare the efficacy and safety of the novel monopegylated interferon alpha 2b AOP2014 versus hydroxyurea (the current licensed therapy for this disease) in both HU naive and currently treated patients, diagnosed with polycythemia vera.

  • PROUD-PV study website
  • Link to the PROUD-PV study on clinicaltrials.gov

Focus: Cardiology

  • A short term pharmacokinetic, pharmacodynamic and tolerability study to compare AOP200704 vs. esmolol.

Products & Area of treatment